Kite Pharma (KITE) Announces Details on CAR/TCR Pipeline, KTE-C19 Launch Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Maxim Remains Positive on Kite Pharma (KITE) Following CAR/TCR Pipeline, KTE-C19 Launch Update; Affirms at 'Buy'
October 19, 2016 11:56 AM EDTMaxim affirms Kite Pharma (Nasdaq: KITE) with a Buy rating and $77 price target on the stock following a pipeline update and KTE-C19... More
Kite Pharma (KITE): Notes From R&D Day - Jefferies
October 19, 2016 7:29 AM EDTJefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after the company's annual R&D investor where the company shared its vision to bring KTE-C19 forward to the market, discussed mfr, reimbursement, and detailed launch strategy. KITE continues to invest in multiple trials for KTE-C19 to drive potentially broader use longer term.... More
Kite Pharma (KITE) Shares Turn Positive in Late Session
October 18, 2016 3:59 PM EDTKite Pharma (NASDAQ: KITE) shares are seeing a late-day pop higher. The stock is now up 0.1 percent.
... MoreKite Pharma (KITE) on Track to Submit KITE-C19 BLA This Year - Investor Day
October 18, 2016 2:58 PM EDTKite Pharma (NASDAQ: KITE) says it is still on track to submit a Biologics License Application (BLA) on KITE-C19 this year, according to Bloomberg, citing today's company webcast.
... MoreKite Pharma (KITE) CMO Chang Says R&D Pipeline 'Well Balanced' Between Blood, Solid Tumors - Investor Day
October 18, 2016 12:50 PM EDTKite Pharma (NASDAQ: KITE) chief medical officer, David D. Chang, M.D., Ph.D., said today that the company's R&D pipeline is "well balanced" between blood and solid tumors. Chang was speaking at Kite's Investor Day today.
Chang also introduced hour... More
Kite Pharma (KITE): CAR T Checks Show Physicians To Be Cautiously Optimistic - Jefferies
October 17, 2016 7:52 AM EDTJefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after attending the Lymphoma & Myeloma meeting where current treatment landscapes and future therapies that included CAR T were discussed.
The analyst believes physicians remain cautiously... More
Kite Pharma (KITE) Shares Tick Higher Pre-Market
October 17, 2016 7:42 AM EDTKite Pharma (NASDAQ: KITE) gained premarket following an appearance by the company's CEO on CNBC.
